Oyster Point is now a part of Viatris - click here

Welcome to the Oyster Point Pharma Multimedia page.

Below, please find our downloadable assets and embed links for use at your discretion.

Important Safety Information

The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.

Indication

Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.

Please click here for full Prescribing Information.

© 2022 Oyster Point Pharma, Inc. Oyster Point®, the Oyster Point logo, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc. in the United States and certain jurisdictions. All rights reserved.

OP-TYR-001378 4/22

Video Resources

How to Use Tyrvaya Video

Embed Script:

<iframe src=”https://player.vimeo.com/video/659063846?h=2b76b7f48f” width=”640″ height=”360″ frameborder=”0″ allow=”autoplay; fullscreen; picture-in-picture” allowfullscreen></iframe>

Link to Player:

https://player.vimeo.com/video/659063846?h=2b76b7f48f 

How to Use Tyrvaya Video (with Closed Captioning)

Embed Script:

<iframe src=”https://player.vimeo.com/video/681090394?h=95ab45e086″ width=”640″ height=”360″ frameborder=”0″ allow=”autoplay; fullscreen; picture-in-picture” allowfullscreen></iframe>

Link to Player:

https://player.vimeo.com/video/681090394?h=95ab45e086

Tyrvaya Mechanism of Action (MOA) Video

Embed Script:

<iframe src=”https://player.vimeo.com/video/636701556?h=d62a9c1b2e” width=”640″ height=”360″ frameborder=”0″ allow=”autoplay; fullscreen; picture-in-picture” allowfullscreen></iframe>

Link to Player:

https://player.vimeo.com/video/636701556?h=d62a9c1b2e